Number 5: Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory ...

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

Bio-Thera Solutions and SteinCares have signed a new agreement to commercialize a proposed biosimilar of dupilumab across ...

This new agreement marks the fourth product in the partnership and introduces a potential cost-effective alternative to one ...

Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory bowel ...

Patients with atopic dermatitis (AD) treated with dupilumab may face a slightly elevated risk of developing psoriasis, with new study data showing a cumulative 3-year incidence of 2.86% compared ...

Dupilumab (Dupixent), a medicine that you get as a shot, is the first new treatment for CSU in the U.S. in over a decade. It’s already used to treat different inflammation conditions in the U.S ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut allergy was not achieved, according to results published in Allergy.“The ...

In a post-hoc analysis, dupilumab improved symptoms of atopic dermatitis (AD) in young children ages 6 months to 5 years. Youngsters with associated comorbidities such as asthma, allergic rhinitis ...

Also, Dupilumab, in collaboration with SNY, is prescribed for pediatric asthma [PA], bullous pemphigoid [BP], and chronic urticaria [CU]. REGN is also developing Eylea HD [aflibercept] for a new ...

She will lead a multicenter controlled trial of 76 children with alopecia affecting at least 30% of the scalp, who will be randomized 2:1 (dupilumab:placebo) for 48 weeks, followed by 48 weeks of ...

Dupilumab was also associated with improvements in lung function (change in pre-bronchodilator FEV 1 from baseline to week 12: 160mL vs 77mL for placebo; P <.0001) that were sustained through 52 ...